Vascutek and Bolton Medical merge as 'Terumo Aortic'

New company brings together two leaders in the aortic implant market

New company brings together two leaders in the aortic implant market

  • New identity underlines global growth ambitions further to $43m factory investment
  • Merger unites two world-class innovators focused on expanding aortic treatment options

Vascutek and Bolton Medical have combined into a single business as it looks to grow its presence in the global aortic and vascular implants market.

Known as Terumo Aortic, the integrated company will become a world leader in driving innovation and developing devices to treat aortic disease. As a combined business, Terumo Aortic aims to become recognised for its focus on individualised treatments that offer clinicians more options than ever before.

Terumo Aortic will have a combined revenue of nearly $200m and over 1,100 employees worldwide. Its primary research and manufacturing facilities will remain in Glasgow, Scotland and Sunrise, Florida.

The combined offering includes advanced technologies such as surgical grafts for abdominal, cardiothoracic and peripheral applications as well as hybrid and catheter-based stent graft systems for abdominal and thoracic aortic aneurysms. These implants have already helped to save or improve the lives of over two million patients in over 100 countries worldwide.

Vascutek and Bolton Medical have been working to consolidate and streamline their complementary offerings for the past year. Significant focus has been placed on creating an integrated research and innovation strategy that will push the boundaries of the aortic and vascular implants market.

Paul Holbrook, President of Terumo Aortic, said: "This coming together of two organisations with highly advanced technologies will be transformative for physicians and the patients they serve."

"We have woven together the products, services and expertise offered by our teams in Scotland and the United States, enabling clinicians to meet the unique needs of their patients and redefine the treatment of aortic disease."